Similar to our observations on the correlation between elevated biomarkers (thyroglobulin and calcitonin) and disease aggressiveness in BRAF-mutated cases, Vrinceanu et al. emphasize the importance of such markers in assessing tumor burden and tailoring treatment to individual patient profiles. This evidence concerns the gene CALCA and neoplasm.